
|Articles|October 8, 2012
FDA gives green light to ANDA for chewable diabetes tablet
FDA has approved Boston Therapeutic’s petition to file an Abbreviated New Drug Application (ANDA) for a new, chewable tablet formulation of the diabetes drug metformin hydrochloride. The company plans to market the new formulation under the name Pazamet.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Pharmacists Can Play Central Role in Patients’ Infusion Services | ASHP Midyear 2025
2
FDA Expands Approval of Flibanserin for Postmenopausal Women’s Sexual Health
3
Women Seek Holistic Interventions for Improving Health Outcomes
4
What TrumpRx Means for Independent Pharmacies and Their Patients
5




























































































































